Close

Durata Therapeutics (DRTX) Receives Positive CHMP Opinion on Xydalba as ABSSSI Treatment

December 19, 2014 7:58 AM EST Send to a Friend
Durata Therapeutics (NASDAQ: DRTX)On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login